Big win for Astellas ($ALPMY ) and Pfizer ( $PFE (-0,08 %) )!
China’s NMPA just approved Padcev™ (enfortumab vedotin) + Keytruda® as the first non-platinum option in 40 years for locally advanced/metastatic urothelial cancer (la/mUC).
🔑 Key Stats from Phase 3 EV-302 Trial:
Overall Survival: 31.5 months (vs. 16.1 with chemo) 🚀
Progression-Free Survival: 12.5 months (vs. 6.3 with chemo) 📉
With over 92K bladder cancer cases in China last year, this approval disrupts decades of reliance on platinum-based chemo and opens a massive market opportunity.
This approval underscores a pivotal shift in treatment options for bladder cancer, providing new opportunities for patients and adding momentum to Astellas and Pfizer’s oncology portfolios.
